secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2026-05-13T20:04:12+00:00
Accession:  0001720580-26-000036
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio Q1 net loss $20.2M; prula-cel Phase 1 data expected mid-2026
-----------------------------------------------------------------------

- Net loss $20.2M ($1.88/share) vs $28.2M ($4.96/share) in Q1 2025; R&D expenses down to $17.5M.
- Cash, cash equivalents and ST investments $137.6M at March 31, 2026; expected runway into H2 2027.
- Phase 1 prula-cel update in mid-2026 with at least 20 LN/SLE patients, min 6 months follow-up.
- FDA interaction in Q2 2026 to inform potential pivotal trial design; plan to start pivotal program in H2 2026.
- Regulatory filing for ADI-212 in mCRPC planned for Q3 2026; Phase 1 enrollment expected Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000172058026000036/0001720580-26-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000172058026000036/acet-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001720580-26-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer